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Background: New World Health Organization guidelines recommend high-risk human papillomavirus (hrHPV)
screen-and-treat strategies for cervical cancer prevention. We describe risk of, and risk factors for, testing hrHPV positive
in a pilot study of hrHPV screen-and-treat conducted in Rwanda.
Methods: A total of 2,964 women, 1,289 HIV-infected (HIV [+]) and 1,675 HIV-uninfected (HIV [-]), aged 30-60 years and
living in Rwanda were enrolled in 2010. Cervical specimens were collected and tested by careHPV, a DNA test for a
pool of 14 hrHPV types. Prevalence with binomial 95% confidence intervals (95% CI) and determinants of testing hrHPV
positive were calculated.
Results: hrHPV prevalence was higher in HIV [+] (31.8%, 95% CI = 29.2-34.4%) than HIV [-] women (8.2%,
95% CI = 6.7-9.8%; P < 0.0001). Among HIV [+] women, there was a significant trend (ptrend <0.001) of higher hrHPV
prevalence with lower CD4 cell count, with the highest hrHPV prevalence among those with <200 CD4 cell counts
(45.5%, 95% CI = 34.8-56.4%). In multivariate analysis of HIV [+] women, testing hrHPV positive was positively associated
CD4 count of <200 cells/μL, history of 3 or more sexual partners, and history of using hormonal contraception, and
negatively associated with older age. In HIV [-] women, testing hrHPV positive was negatively associated only with
older age groups of 45-49 and 50-60 years and surprisingly was not associated with lifetime number of sexual partners.
Conclusion: hrHPV prevalence is high in HIV [+], especially in women with the lowest CD4 cell counts, which may
have implications for utilizing hrHPV-based screening strategies such as screen-and-treat in these high-risk subgroups.
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Globally, cervical cancer is the third most common female
cancer and cause of female cancer-related deaths, with an
estimated 530,000 cases and 265,653 deaths annually,
respectively [1]. In low- and middle-income countries
(LMICs), cervical cancer is often the most common
cancer, the leading cause of cancer-related mortality,
and a leading cause of all-cause mortality in women due
to a lack of preventive services. Cervical cancer constitutes* Correspondence: sinayobyed@gmail.com
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unless otherwise stated.13% of all female cancers in LMICs [2,3]. More than 85%
of cervical cancer deaths occur in LMICs [3]. Approxi-
mately one quarter of cervical cancers and related mortal-
ity globally occur in Africa, and >90% of those occur in
Sub-Saharan Africa, which has an overall age-standardized
rate of cervical cancer incidence of 34.8 per 100,000.
Introduction of large-scale cervical cancer cytology-
based screening programs, utilizing the Papanicolaou
(Pap) smear has dramatically reduced cervical cancer in-
cidence and mortality in developed countries [4]. For
example, an estimated 45% of all cervical cancer was pre-
vented over a 50-year period (1961-2010) by the introduc-
tion of cervical cytology-based screening in Denmark,tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ity of cytological screening and inadequate health infra-
structure, in addition to the lack of human resource
capacity, make this screening approach impractical and
unsustainable in the developing world [6,7].
Persistent cervical infection by approximately 12-15 car-
cinogenic or high-risk human papillomavirus (hrHPV)
genotypes causes virtually all cervical cancer and its im-
mediate precursors [8-10]. HPV genotype 16 (HPV16)
causes approximately 55% and HPV18 causes approxi-
mately 15% of cervical cancers [11]. HrHPV infections are
typically transient and clear or become undetectable
within 1-2 years [8,12]. Those hrHPV infections that
persist for even one year [13] or two years [14] strongly
predict the development of cervical precancer and cancer.
The discovery that persistent hrHPV is the cause of
cervical cancer has led to technological developments,
including molecular hrHPV testing for cervical cancer
screening. Molecular hrHPV testing is more sensitive
[15-20] and reliable [21-23] for detection of cervical
intraepithelial neoplasia (CIN3), adenocarcinoma in situ
(AIS), or invasive cervical cancer (≥CIN3) than Pap test-
ing. The increased sensitivity of hrHPV testing over Pap
testing for ≥CIN3 translates into two important benefits:
1) earlier detection of all high grade lesions that if
treated results in a reduced incidence of cervical cancer
within 4-5 years [24] and related death within 8 years
[25] and 2) greater reassurance against cancer (lower
cancer risk) for many years following a negative result
[24-28], which permits screening at an extended interval
of 5-10 years. The World Health Organization (WHO)
has recently recommended hrHPV testing and visual in-
spection after acetic acid (VIA) as alternatives to Pap test-
ing for those countries that do not have high-coverage
Pap testing [29]. If the resources are available, hrHPV test-
ing is recommended, either alone or with VIA evaluation
of hrHPV positives, although using VIA as a triage of
hrHPV positives may significantly reduce the sensitivity of
screening [29,30].
Current U.S. Food and Drug Administration (FDA) ap-
proved hrHPV tests are too costly and complex to use in
many settings in LMICs. To address the need for a sim-
pler, lower-cost hrHPV test for LMICs, careHPV™ (Qiagen,
Gaithersburg, MD, USA) was developed based on the
same chemistry as its U.S. FDA approved predecessor,
Hybrid Capture 2 (HC2; Qiagen). careHPV is a DNA test
for a pool of 13 hrHPV genotypes (HPV16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 68) and one possibly hrHPV geno-
type (HPV66). Previous studies have shown that careHPV
has good sensitivity and specificity for cervical precancer
and cancer that approaches HC2 [31,32] and performs rea-
sonably well using self-collected specimens [31-33].
Data from developing countries on the overall hrHPV in-
fection prevalence and associated risk factors is imperativeto develop and guide screening strategies particularly in
Sub-Saharan Africa, which bears the greatest dual burden
of human immunodeficiency virus (HIV) infection and
cervical cancer. To date, information on hrHPV preva-
lence and associated risk factors in the HIV-infected
population comes from a few African countries such as
Kenya, Nigeria, Cameroun and South Africa [34-38].
There is uncertainty about how generalizable these data
are to HPV infection patterns in other African settings
with varying cultural and social dynamic characteristics.
HIV is known to be associated with higher prevalence
and persistence of HPV infection [39,40]. A previous re-
port on 188 HIV-uninfected (HIV [-]) and 628 HIV-
infected (HIV [+]) Rwandan women found ~5-fold higher
prevalence of hrHPV in antiretroviral (ART)-naïve, HIV
[+] compared to HIV [-] women. However, in this study,
only women living in an urban setting were included,
none of the HIV [+] women was receiving ART, and only
a small number of HIV [-] women were recruited. Thus,
the generalizability of those findings to Rwanda and
other countries is limited.
In 2010, we conducted a sentinel evaluation of
screen-and-treat strategies, prior to the launch of na-
tional program of hrHPV screen-and-treat in Rwanda
[41] anticipated for 2014 and the endorsement of such
a strategy by the WHO in late 2013 [29]. We recruited
approximately 1,300 HIV [+] and 1,700 HIV [-] women
into the evaluation. All women were screened by careHPV
and VIA and was treated by cryotherapy if hrHPV or VIA
positive (n.b., VIA was used as a screen and not as a triage
for hrHPV-positive women.). At enrollment, we collected
data on risk factors through an administered question-
naire. Here we present the prevalence of and risk factors
for hrHPV by HIV status in these Rwandan women, which
has implications for implementation of the careHPV-
based screening program there.
Methods
Study population
This is a cross-sectional analysis of 2,964 women, 1,289
HIV [+] and 1,675 HIV [-], women aged 30-60 years,
and living in Rwanda. Figure 1 presents a consort dia-
gram of enrolled women and exclusions by HIV status.
Women were recruited from Nduba and Jabana sectors
served by the Nyacyonga Public Health Center under
the Kibagabaga District Hospital in Gasabo district, with
1,000 of the HIV [+] women recruited from an HIV-
dedicated clinic in Kigali. The study population was a
mix of women living in urban and rural settings to in-
crease the representativeness of the Rwandan population.
Most of the recruitment was done through community-
based outreach teams of Community Health workers
(CHWs) who were trained as cervical cancer educators.
Inclusion criteria were age 30-60 years, ability and
Figure 1 Consort diagram for the 2,971 human immunodeficiency virus-infected (HIV [+]) and uninfected (HIV [-]) women aged 30-60
years and living in Rwanda enrolled and tested for high-risk human papillomavirus DNA by careHPV.
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procedures, have an HIV test, and blood drawn for
CD4 cell count determination if found to be HIV posi-
tive. Past history of cervical cancer screening and/or
being pregnant was an exclusion criterion.
The study protocol and written informed consent process
were approved by the Rwanda National Ethics Committee
and the Institutional Review Board of Montefiore Medical
Center (Bronx, NY). Trained research teams gathered
medical history focusing on reproductive and sexual
health through a short interview from consenting women.
The consent interview was done in Kinyarwanda (national
Rwandan language), which was translated from the ori-
ginal English version by experts in the two languages and
there were no specific exclusionary factors regarding lan-
guage. A speculum exam was performed with the collec-
tion of an endocervical specimen using a “Christmas tree
brush”, placed into DCM™ medium (Qiagen) for careHPV
testing.
All women whose HIV tests were positive had blood
drawn for CD4 cell count, and were referred to a nearby
public health center for CD4+ count determination and
HIV care and treatment. HIV infection was diagnosed by
a testing algorithm, which included 2 commercial HIV-1
antibodies enzyme-linked immunosorbent assay kits (HIV
Vironostika, Netherlands, and Murex HIV-1.2, Oxford,
UK). CD4 counts were determined with a flow-activated
cell counter (Becton and Dickinson, Immunocytometry
Systems, San Jose, CA, USA). The HIV infection and CD4
results were provided to the treatment site by the program
outreach staff.
Case definition and secondary variables
HrHPV infection, a dichotomous outcome variable, was
defined as having a positive careHPV DNA test. We
considered as potential covariates the following variables
found to be related to testing hrHPV positive in previous
studies or otherwise biologically plausible; HIV related
immunological status (CD4), current age, menopausalstatus, age at sexual debut, age at first pregnancy, parity,
history of malaria, tobacco use, hormonal contraceptive
use, lifetime number of sexual partners, polygamous re-
lationship, rape history, and ART use.Statistical analysis
Data were analyzed using STATA 11.1 (StataCorp LP, Col-
lege Station, TX, 2010). Descriptive analyses including
means, standard deviations, medians and interquartile
ranges were performed for continuous variables, and per-
centages for categorical variables. This was stratified by
HIV status and by CD4 count (≥500, >350-499, 200-349
and <200 cells/μl) for HIV-infected women. The same de-
scriptive statistical analysis of baseline demographic and
clinical characteristics were stratified both by HIV infected
vs. uninfected women and by hrHPV status. Analysis of
variance and non-parametric Kruskal Wallis tested for
statistical differences of continuous variables across differ-
ent HIV, CD4 and hrHPV infection groups. Chi-square
tests and logistic regression analysis assessed the associ-
ation of categorical variables (including HIV/CD4 status)
with hrHPV infection categories. All covariates in Table 1
were considered for multivariable logistic regression
models as they had been found to be associated with HPV
infection in previous studies or because of biological
plausibility. However, body mass index (BMI) and age at
sexual initiation had a considerable amount of missing
values and were thus excluded from multivariate analyses
to prevent data loss.
To avoid potential investigator bias by selecting or
weighting variables for inclusion, stepwise selection lo-
gistic regression with p value to enter and stay of 0.10
was used to build two separate multivariate predictive
models of hrHPV infection, one for HIV [+] and one for
HIV [-] women. Odds Ratios (OR) and 95% confidence
intervals (95% CI) were calculated as indicators of the
magnitude of association and statistical significance of
hrHPV infection.
Table 1 Baseline Characteristics by HIV and Immunological level (CD4 count) in both HIV-infected (HIV [+]) and





p* HIV[+] N = 1,228 p**
CD4: ≥500 CD4:350-499 CD4:200-349 CD4:<200
N = 513 N = 346 N = 271 N = 88
Age, years, mean ± SD 42.0 ± 8.2 40.0 ± 6.6 <0.001 39.8 ± 6.6 40.1 ± 6.7 40.8 ± 6.5 39.7 ± 6.5 0.21
Age category, years, n (%) <0.001 0.17
Age 30 – 34 299 (22.8) 278 (22.6) 127 (24.8) 81 (23.4) 51 (18.8) 16 (18.2)
Age 35 – 39 279 (21.3) 359 (29.3) 144 (28.1) 101 (29.2) 76 (28.0) 35 (39.8)
Age 40 – 44 237 (18.1) 295 (24.0) 134 (26.1) 80 (23.1) 63 (23.3) 17 (19.3)
Age 45 – 49 211 (16.1) 171 (13.9) 58 (11.3) 49 (14.2) 49 (18.1) 13 (14.8)
Age at sexual initiation, years, n (%) <0.001 0.01
Age <14 16 (4.2) 30 (10.2) 11 (10.0) 5 (5.1) 7 (11.9) 7 (28.0)
Age 14 – 25 338 (89.7) 258 (87.8) 97 (89.0) 92 (93.9) 49 (83.0) 17 (68.0)
Age at first pregnancy, years ± SD 21.1 ± 3.7 20.1 ± 3.6 <0.001 20.1 ± 3.6 20.3 ± 3.6 20.0 ± 3.7 19.4 ± 3.4 0.25
Lifetime sexual partners <0.001 0.59
1- 2 sexual partners 1132 (86.4) 616 (50.2) 260 (50.7) 179 (51.7) 126 (46.5) 43 (48.9)
≥3 sexual partners 179 (13.6) 612 (49.8) 253 (49.3) 167 (48.3) 145 (535) 45 (51.1)
Number of children delivered, n (%) <0.001 0.01
0 – 2 300 (23.7) 448 (39.6) 163 (33.9) 130 (41.3) 117 (47.8) 37 (44.6)
3 – 4 500 (39.5) 464 (41.0) 211 (43.9) 122 (38.7) 93 (37.9) 33 (39.7)
5 – 12 466 (36.8) 219 (19.4) 107 (22.2) 63 (20.0) 35 (14.3) 13 (15.7)
Rape, n (%) <0.001 0.46
Yes 187 (14.3) 409 (33.3) 164 (32.0) 124 (35.8) 85 (31.4) 33 (37.5)
No 1123 (85.7) 819 (66.7) 349 (68.0) 222 (64.2) 186 (68.6) 55 (62.5)
Menopause, n (%) <0.001 0.58
Yes 219 (16.7) 111 (9.0) 50 (9.7) 26 (7.5) 28 (10.3) 7 (8.0)
No 1092 (83.3) 1117 (91.0) 463 (90.3) 320 (92.5) 243 (89.7) 81 (92.0)
Polygamous relationship, n (%) 0.01 0.81
Yes 60 (9.2) 34 (14.9) 15 (15.9) 8 (12.1) 8 (15.4) 3 (21.4)
No 593 (90.8) 194 (85.1) 79 (84.1) 58 (87.9) 44 (84.6) 11 (78.6)
Ever used hormonal contraceptives, n (%) 0.002 < 0.001
Yes 393 (30.1) 305 (24.8) 154 (30.1) 86 (24.9) 45 (16.6) 20 (22.7)
No 912 (69.9) 922 (75.2) 358 (69.9) 260 (75.1) 226 (83.4) 68 (77.3)
Ever used tobacco, n (%) <0.001 0.57
Yes 221 (16.9) 57 (4.6) 25 (4.9) 11 (3.2) 13 (4.8) 5 (5.8)
No 1089 (83.1) 1169 (95.4) 488 (95.1) 335 (96.8) 258 (95.2) 81 (94.2)
Antiretroviral therapy, n (%) < 0.001
Yes N/A 948 (78.1) 342 (67.6) 273 (79.6) 274 (92.2) 82 (93.2)
No N/A 266 (21.9) 164 (32.4) 70 (20.4) 21 (7.8) 6 (6.8)
Malaria within 6 months, n (%) <0.001 0.28
Yes 185 (14.0) 95 (7.8) 47 (9.2) 23 (6.6) 16 (5.9) 5 (5.7)
No 112 4(86.0) 1133 (92.2) 466 (90.8) 323 (93.4) 255 (94.1) 83 (94.3)
BMI, mean ± SD, kg/m^2 21.9 ± 3.7 22.6 ± 3.8 <0.001 23.0 ± 3.8 22.7 ± 3.8 22.1 ± 3.8 22.0 ± 3.4 0.01
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Table 1 Baseline Characteristics by HIV and Immunological level (CD4 count) in both HIV-infected (HIV [+]) and
-uninfected {HIV [-]) women (Continued)
BMI, n (%), kg/m2 <0.001 0.38
12.5 – 18.5 136 (15.7) 135 (11.6) 44 (9.3) 41 (12.4) 38 (14.3) 11 (12.6)
18.5 – 21.0 243 (28.1) 282 (24.3) 113 (23.8) 77 (23.3) 68 (25.6) 24 (27.6)
> 21 – 39.5 486 (56.2) 744 (64.1) 318 (66.9) 212 (64.3) 160 (60.1) 52 (59.8)
HrHPV infection, n (%)* <0.001 0.02
Yes 107 (8.2) 390 (31.8) 156 (30.4) 103 (29.8) 91 (33.6) 40 (45.5)
No 1,204 (91.8) 838 (68.2) 357 (69.6) 243 (70.3) 180 (66.4) 48 (54.5)
SD, standard deviation and BMI, Body Mass Index. P*-value is for comparing HIV-uninfected to infected overall. P**-value is for comparing CD4 categories in HIV
-infected women to different subjects’ parameters. For obtaining p-values chi-Square tests were used for categorical variables and ANOVA for continuous variables
except: number of children born, where non-parametric Kruskal Wallis tests was used.
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Participants’ baseline demographic and clinical character-
istics by HIV status and among HIV [+] immunological
status (CD4+ cell count categories) are summarized
(Table 1). Comparing HIV [+] and HIV [-] women, HIV
[-] were older, older at sexual initiation, older at first preg-
nancy, had delivered more children, more likely to ever
use hormonal contraceptives, more likely to ever use to-
bacco, have a prior episode of malaria, and had a lower
BMI compared to HIV [+] women (p < 0.05 for all). By
comparison, HIV [+] had more sexual partners in their
lifetime, were more likely to have a polygamous relation-
ship, reported a history of rape, and tested positive for
hrHPV than HIV [-] women (p < 0.05 for all). Because the
populations were distinct, we elected to conduct our ana-
lyses separately in HIV [+] and HIV [-] populations rather
than combine populations.
Among HIV [+] women, women with lower CD4 counts
(more immunosuppressed) had fewer children, were less
likely to use hormonal contraceptives, had a lower BMI,
and were more likely to test hrHPV positive.
Tables 2 and 3 summarize baseline demographic and
clinical characteristics by hrHPV status in HIV [+] and
HIV [-] women, respectively. Among HIV [+] women,
hrHPV-infected women were younger, younger age at first
pregnancy, had lower CD4 cell count, fewer lifetime sex-
ual partners and less number of hormonal contraceptive
(p <0.05 for all). Among HIV [-] women, hrHPV infected
women were younger, and fewer post-menopausal status
(p <0.05 for all).
The prevalence of hrHPV by HIV status and CD4
counts, by HIV status and age, and by HIV status, CD4
counts, and age are shown in Figure 2 (Panels A, B, and
C, respectively). Overall, hrHPV prevalence was higher in
HIV [+] women (31.8%, 95% CI = 29.2-34.4%) than HIV
[-] women (8.2%, 95% CI = 6.7-9.8%) (p < 0.001). HIV [+]
women who were more immune suppressed tended to
have a greater prevalence of hrHPV (30.4%, 29.8%, 33.6%
and 45.5% hrHPV prevalence for CD4+ cell count cat-
egories of ≥500, 350 – 499, 200-349 and <200 cells/μL,respectively) (ptrend <0.001) (Figure 2A). HrHPV preva-
lence declined with increasingly older age groups in HIV
[+] women, from 46.8% in 30-34 years to 26.4% in 50-60
years (ptrend <0.001), and HIV [-] women, from 11.7%
in 30-34 years to 4.5% in 50-60 years (ptrend <0.001)
(Figure 2B). Among HIV [+], hrHPV prevalence declined
with age for every category of CD4 cell count (Figure 2C).
Table 4 presents the results of the multivariate model
for risk factors for hrHPV in HIV [+] women. A CD4
count of <200 cells/μL (vs. ≥500 cells/μL) was associated
with testing hrHPV positive (adjusted Odds Ratio (aOR) =
2.21; 95% CI = 1.37 – 3.55) but CD4 counts of 200-349 or
350-499 cells/μL (Vs. ≥500 cells/μL) were not. Among
HIV [+] women, age groups older than 30-34 years were
independently approximately 2-fold less likely to test
hrHPV positive compared to 30-34 year olds, but ART
use was not independently associated with testing hrHPV
positive. HIV [+] women with history of 3 or more lifetime
number of sexual partners (vs. 1–2 lifetime number of
sexual partners) were more likely to test hrHPV positive
(aOR = 1.6; 95% CI = 1.2-2.0) while HIV [+] women with
a history of using hormonal contraceptives were more
likely to test hrHPV positive than those who did not
(aOR = 1.5; 95% CI = 1.1–2.0).
Table 5 presents the results of the multivariate model
for risk factors for hrHPV in HIV [-] women. Only older
age was independently (negatively) associated with test-
ing hrHPV positive, with HIV [-] women aged 50-60 be-
ing the least likely to test hrHPV positive (aOR = 0.36;
95% CI = 0.19 – 0.69). Surprisingly, having 3 or more life-
time number of sexual partners (vs. 1-2 lifetime number
of sexual partners) was negatively associated with testing
hrHPV positive in HIV [-] women, although this finding
was not statistically significant. However, few HIV [-]
women reported having more than 3 or more lifetime
number of sexual partners.
Discussion
We found a more three-fold higher prevalence of hrHPV
infection in HIV [+] than HIV [-] Rwandan women. This
Table 2 Baseline characteristics by high-risk human







N = 390 N = 838
Age, years, mean ± SD 38.9 ± 6.7 40.7 ± 6.5 < 0.001
Age category, years, n (%) < 0.001
Age 30 – 34 130 (46.8) 148 (53.2)
Age 35 – 39 100 (27.9) 259 (72.1)
Age 40 – 44 83 (28.1) 212 (71.9)
Age 45 – 49 44 (25.7) 127 (74.3)
Age 50 – 61 33 (26.4) 92 (73.6)
CD4 cell count, n (%) 0.03
CD4 cell count, ≥500 156 (30.4) 357 (69.6)
CD4 cell count, 350 – 499 103 (29.8) 243 (70.2)
CD4 cell count, 200 – 349 91 (33.6) 180 (66.4)
CD4 cell count, <200 40 (45.5) 48 (54.5)
Age at sexual debut, years,
n (%)
0.27
Age <14 9 (30.0) 21 (70.0)
Age 14 – 25 78 (30.2) 180 (69.8)
Age at first pregnancy,
years ± SD
19.6 ± 3.2 20.3 ± 3.7 < 0.01
Lifetime sexual partners < 0.001
1- 2 sexual partners 167 (27.1) 449 (72.9)
≥ 3 sexual partners 223 (36.4) 389 (63.6)
Number of children delivered,
mean ± SD
3.0 ± 1.6 3.1 ± 1.7 0.21
Number of children delivered,
n (%)
0.15
0 – 2 150 (33.5) 298 (66.5)
3 – 4 158 (34.0) 306 (66.0)
5 – 12 59 (27.0) 160 (73.0)
Rape, n (%)
Yes 135 (33.0) 274 (67.0) 0.50
No 255 (31.1) 564 (68.9)
Menopause, n (%) 0.07
Yes 27 (24.3) 84 (75.7)




Yes 13 (38.2) 21 (61.8)




Yes 126 (41.3) 179 (58.7)
No 264 (28.6) 658 (71.4)
Table 2 Baseline characteristics by high-risk human
papillomavirus (hrHPV) status, restricted to HIV-infected
(HIV [+]) women (Continued)
Ever used tobacco, n (%) 0.78
Yes 19 (33.3) 38 (66.7)
No 369 (31.6) 800 (68.4)
Antiretroviral therapy, n (%) 0.63
Yes 307 (32.4) 641 (67.6)
No 82 (30.8) 184 (69.2)
Malaria within 6 months,
n (%)
0.34
Yes 26 (27.4) 69 (72.6)
No 364 (32.1) 769 (67.9)
BMI, mean ± SD, kg/m^2 22.7 ± 3.6 22.6 ± 3.8 0.59
Chi-square test for categorical variables and ANOVA for continuous.
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Africa and elsewhere [34,36,39,42,43]. In two previous
Rwanda studies, a higher prevalence of hrHPV infection
was found in HIV [+] than in HIV [-] Rwandan women
for all age groups: (25 -34 years, 50% vs. 16%; 35 - 44 years,
42% vs. 8%; 45 -54, 33% vs. 5%) in the first study and (all
ages, 50.8% vs. 31.8%) in the second study [7,42].
However, hrHPV prevalence in HIV [+] women in this
study was lower compared that reported from other
studies of HIV [+] women [25,27,34,42]. This may be
due to the fact that this was a population-based study
with community recruitment and a high proportion of
women were on ART (78.1%), whereas other studies did
not include women on ART [34,44] or recruited mainly
sexually high-risk populations [34,42].
Among HIV [+] women included in this study, severe
immunosuppression (CD4 cell count: <200 vs. ≥500
cells/μL) was independently associated with hrHPV in-
fection in HIV [+] women; other investigators reported
similar findings [34,42,45]. Because we only have preva-
lence data from our cross-sectional study, we cannot de-
termine whether the effect of immunosuppression was
to increase susceptibility of infection (incidence), the
likelihood of persistence, and/or reactivation of quies-
cent infections [46]. To discriminate between these ex-
planations and to understand the natural history of HPV
and the associated risks for ≥CIN3 in HIV [+] women
living in Sub-Saharan Africa, large, well-powered cohort
studies with longitudinal follow-up are needed.
Our study also found that among HIV [+] women hor-
monal contraception was independently associated with
hrHPV infection. It is unclear if contraception was a
marker for more risky sexual behavior and condom non-
use or could be otherwise directly causal through hor-
mones. But our finding with regard to the association
hrHPV and hormonal contraception was inconsistent
Table 3 Baseline characteristics by high-risk human







N = 107 N = 1,204
Age, years, mean ± SD 39.5 ± 7.1 42.3 ± 8.3 < 0.001
Age category, years, n (%) 0.01
Age 30 – 34 35 (11.7) 264 (88.3)
Age 35 – 39 22 (7.9) 257 (92.1)
Age 40 – 44 24 (10.1) 213 (89.9)
Age 45 – 49 13 (6.1) 198 (93.9)
Age 50 – 61 13 (4.6) 272 (95.4)
Age at sexual debut, years, n (%) 0.77
Age <14 1 (6.2) 15 (93.8)
Age 14 – 25 28 (8.3) 310 (91.7)
Age at first pregnancy,years ± SD 20.5 ± 3.8 21.2 ± 3.7 0.07
Lifetime sexual partners < 0.001
1- 2 sexual partners 99 (8.7) 1033 (91.3) 0.05
≥ 3 sexual partners 8 (4.5) 171 (95.5)
Number of children born,
mean ± SD
3.7 ± 1.6 3.9 ± 1.8 0.24
Number of Children born, n (%) 0.40
0 – 2 23 (7.7) 277 (92.3)
3 – 4 46 (9.1) 458 (90.9)
5 – 12 32 (6.8) 437 (93.2)
Rape, n (%) 0.74
Yes 14 (7.5) 173 (92.5)
No 92 (8.2) 1031 (91.8)
Menopause, n (%) 0.03
Yes 10 (4.6) 209 (95.4)
No 97 (8.9) 995(91.1)
Polygamous relationship, n (%) 0.54
Yes 6 (10.0) 54 (90.0)




Yes 33 (8.4) 360 (91.6)
No 73 (8.0) 839 (92.0)
Ever used tobacco, n (%) 0.42
Yes 15 (6.8) 206 (93.2)
No 92 (8.4) 1004 (91.6)
Malaria within 6 months, n (%) 0.77
Yes 14 (7.6) 171 (92.4)
No 92 (8.2) 1032 (91.8)
BMI, mean ± SD, kg/m^2 21.9 ± 3.5 21.9 ± 3.7 0.98
Chi-square test for categorical variables and ANOVA for continuous.
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HIV-infected Canadian women, in which there was no
association with hormonal contraceptive use and hrHPV
prevalence. Given the magnitude of association of hor-
monal contraceptives in the present study and the high
use rate of hormonal contraception in Africa, more
studies of African HIV [+] women are needed to clarify
this relationship.
Although we did not compare HIV [+] and HIV [-]
women directly in a multivariate model due to differ-
ences in the risk factor profiles for the two populations,
HIV infection appears to be an independent risk factor
for hrHPV, as even HIV [+] women with CD4 counts
of ≥500 cells/mL had a more than 3-fold greater hrHPV
prevalence than HIV [-] women. A similarly high magni-
tude of association of HIV infection with hrHPV was
previously found in a Ugandan population: aOR = 4.82,
95% CI = 3.10-7.53 [51]. Two other studies previously
showed that HIV-infected women are more likely than
those without HIV infection to have persistent HPV
[52,53]. But with respect to HPV natural history, there is
an incomplete re-constitution of immune response to
HPV with ART. ART itself was not an independent pre-
dictor of hrHPV prevalence but its effects were likely
mediated through CD4 counts.
Although prophylactic HPV vaccines may prove to be
the ultimate cervical cancer prevention strategy, there
are already 2-3 generations of at-risk, hrHPV-positive
women who will not benefit from HPV vaccination, and
universal HPV vaccination is decades away. Moreover, in
the ART era, HIV [+] women will live longer, have a
greater hrHPV burden, and in the absence of compre-
hensive screening and treatment, will likely remain at an
elevated risk of invasive cervical cancer. Thus, there is
still a need to better understand what comprises an ef-
fective immune response against HPV infection. Such
research may provide important clues to the development
of effective biological therapeutics against HPV and HPV-
related disease that might be used to prevent HPV-related
cancers in those already infected with hrHPV. Our study
had limitations mainly due to the cross sectional design
with potential problems with direction of causality, which
means that HPV could possibly increase the likelihood
of HIV infection or vice versa. Recent evidence suggests
that HPV infection can increase the risk of HIV acquisi-
tion [54].
In conclusion, we found that HIV [+] women had a
higher hrHPV prevalence than HIV [-] women, and that
the hrHPV prevalence in HIV [+] women was inversely
related to immune suppression as measured by CD4 cell
counts. Our data have important implications for hrHPV-
based screening in HIV [+] women living in Rwanda and
elsewhere. In the general population, hrHPV-based screen
and treat, in which all hrHPV-positive women are treated
Figure 2 Percent careHPV positive (high-risk HPV prevalence) by HIV status and CD4 count category (A), by age group for HIV status (B),
and by age group and CD4 category among HIV+women (C). In Figure 1C, for CD4 < 200 (only), age groups 45-49 and 50+ years were combined
due to small numbers (indicated by *).
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Table 4 Factors associated with high-risk human papillomavirus among HIV [+] women as determined using univariate
and multivariate logistic regression
Parameters Unadjusted model Adjusted model
Odds ratio 95% CI Odds ratio 95% CI
Age category, years, n (%)
Age 30 – 34 (Ref.) 1.0 1.0
Age 35 – 39 0.44 0.32 – 0.61 0.44 0.31 – 0.61
Age 40 – 44 0.45 0.32 – 0.63 0.47 0.33 – 0.68
Age 45 – 49 0.39 0.26 – 0.60 0.42 0.27 – 0.65
Age 50 – 61 0.41 0.26 – 0.65 0.49 0.30 – 0.79
CD 4 cell count, cells/ μL
CD4 cell count, ≥500 (Ref.) 1.0 1.0
CD4 cell count, 350 – 499 1.0 0.74 – 1.3 1.0 0.76 – 1.4
CD4 cell count, 200 – 349 1.2 0.87 – 1.6 1.3 0.95 – 1.8
CD4 cell count, <200 2.0 1.2 – 3.1 2.2 1.4 – 3.6
Lifetime sexual partners: ≥3 vs. 1-2 1.5 1.2 – 2.0 1.6 1.2 – 2.0
Ever used hormonal Contraceptives: Yes vs. No 1.8 1.3 – 2.3 1.5 1.11– 2.0
Ever used tobacco use, Yes vs. No 1.1 0.62 – 1.9
Ever been raped, Yes vs. No 1.1 0.85 – 1.4
Antiretroviral Treatment: Yes vs. No 1.1 0.80 – 1.4
Number of children delivered 0.95 0.88 – 1.0
Malaria within 6 months, Yes vs. No 0.80 0.50 – 1.3
Menopause, Yes vs. No 0.67 0.43 – 1.1
Stepwise Logistic regression with entry and stay p = 0.1.
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relatively few women who will be treated and the lack
of colposcopist and pathologists [55] to provide tissue-
based diagnosis to guide treatment. However, in the
HIV [+]women, especially those who are highly immuneTable 5 Factors associated with high-risk human papillomavi
and multivariate logistic regression
Parameters Unadjusted
Odds ratio
Age category, years, n (%)
Age 30 – 34 (Ref.) 1.0
Age 35 – 39 0.64
Age 40 – 44 0.85
Age 45 – 49 0.50
Age 50 – 61 0.36
Lifetime sexual partners: ≥3 vs. 1-2 0.49
Ever used hormonal Contraceptives: Yes vs. No 1.1
Ever used tobacco use, Yes vs. No 0.79
Ever been raped, Yes vs. No 0.91
Number of children borne 0.93
Malaria within 6 months, Yes vs. No 0.92
Menopause, Yes vs. No 0.49
Stepwise Logistic regression with entry and stay p = 0.1.suppressed and are likely to be at the greatest risk of cer-
vical cancer [56] and [57], hrHPV-based screening may be
to non-specific to use alone, especially in a screen-and-
treat strategy. In the Rwandan context, half of these highly
immune suppressed women would test hrHPV positiverus among HIV [-] women as determined using univariate
model Adjusted model
95% CI Odds ratio 95% CI
1.0
0.37 – 1.1 0.64 0.37 – 1.1
0.49 – 1.5 0.85 0.49 – 1.5
0.26 – 0.96 0.49 0.25 – 0.96
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portion would be treated [25,27,34,42]. Thus, it may be
desirable to use a secondary, triage test to determine
which hrHPV-positive women need immediate treatment
(triage positive) and which might have treatment deferred
(triage negative) until there is evidence of hrHPV persist-
ence, which is a strong risk factor for cervical precancer
and cancer [12,13].
Although VIA has been proposed, as mentioned, VIA
as a triage of hrHPV positives may significantly reduce
the overall sensitivity of screening [29,30]. Alternatively,
very specific biomarkers, such as HPV E6 oncoprotein
[32,58] might be considered but has not been evaluated
in this population.
Further investigations are need to determine the opti-
mal cervical cancer screening strategies, those that bal-
ance the benefits and harms of screening, in known HIV
[+] women living in Africa.
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